Blood clotting abnormalities reveal COVID-19 patients at risk for thrombotic events

Journal of the American College of Surgeons article highlights early research on blood clotting evaluation work that may help identify and treat dangerous complications of the infection

Newswise —

CHICAGO (May 15, 2020): When researchers from the University of Colorado Anschutz Medical Campus, Aurora, used a combination of two specific blood-clotting tests, they found critically ill patients infected with Coronavirus Disease 2019 (COVID-19) who were at high risk for developing renal failure, venous blood clots, and other complications associated with blood clots, such as stroke. Their study, which was one of the first to build on growing evidence that COVID-19-infected patients are highly predisposed to developing blood clots, linked blood clotting measurements with actual patient outcomes. The research team is now participating in a randomized clinical trial of a drug that breaks down blood clots in COVID-19-infected patients. “This is an early step on the road to discovering treatments to prevent some of the complications that come with this disease,” said Franklin Wright, MD, FACS, lead author of the research article and an assistant professor of surgery at the University of Colorado School of Medicine. Their research is published as an “article in press” on the Journal of the American College of Surgeons website ahead of print.

Patients who are critically ill regardless of cause can develop a condition known as disseminated intravascular coagulation (DIC). The blood of these patients initially forms many clots in small blood vessels. The body’s natural clotting factors can form too much clot or eventually not be able to effectively form any clot leading to issues of both excessive clotting and excessive bleeding. However, in patients with COVID-19 the clotting appears to be particularly severe and—as evidenced by case studies in China and elsewhere1—clots in COVID-19 patients do not appear to dissipate, explained Dr. Wright.

Trauma acute care surgeons and intensive care physicians who treat trauma, transplant, and cardiothoracic surgery patients at the UCHealth University of Colorado Hospital saw the potential of using a specialized coagulation test to examine clotting issues in COVID-19 patients. Thromboelastography (TEG) is a whole blood assay that provides a broad picture of how an individual patient’s blood forms clots, including how long clotting takes, how strong clots are, and how soon clots break down. TEG is highly specialized and used primarily by surgeons and anesthesiologists to evaluate the efficiency of blood clotting; it is not widely used in other clinical settings. “The COVID pandemic is opening doors for multidisciplinary collaboration so trauma acute care surgeons and intensivists can bring the tools they use in their day-to-day lives and apply them in the critical care setting to new problems,” Dr. Wright said.

The researchers evaluated outcomes for all patients who had a TEG assay as part of their treatment for COVID-19 infection as well as other conventional coagulation assays, including ones that measure D-dimer levels. D-dimer is a protein fragment that is produced when a blood clot dissolves. D-dimer levels are elevated when large numbers of clots are breaking down.

A total of 44 patients treated for COVID-19 infection between March 22 and April 20 were included in the analysis. Those whose bodies were not breaking down clots most often required hemodialysis and had a higher rate of clots in the veins. These patients were identified by TEG assays showing no clot breakdown after 30 minutes and a D-dimer level greater than 2600 ng/mL. Eighty percent of patients with both affirmative test findings were placed on dialysis compared with 14 percent who tested for neither finding. Patients with affirmative test findings also had a 50 percent rate of venous blood clots compared with 0 percent for those patients with neither finding.

“These study results suggest there may be a benefit to early TEG testing in institutions that have the technology to identify COVID-19 patients who may need more aggressive anticoagulation therapy to prevent complications from clot formation,” Dr. Wright said.

A clinical trial of one form of treatment is already underway. The Denver Health and Hospital Authority is leading a multi-center study that includes UCHealth University of Colorado Hospital, National Jewish Health-St Joseph Hospital, Beth Israel Deaconess Medical Center, and Long Island Jewish Hospital in conjunction with Genentech, Inc., enrolling patients with  COVID-19 infection in a randomized clinical trial of tissue plasminogen activator (tPA). This drug is a clot-busting, thrombolytic medicine that was first approved by the U.S. Food and Drug Administration in 1987 for the treatment of heart attack and later approved for acute massive pulmonary embolism and acute ischemic stroke.2 * The trial will assess the efficacy and safety of intravenous tPA in improving respiratory function and management of patients with aggressive blood clotting.

“This study suggests that testing whole blood clotting measurements may allow physicians to identify and treat patients with COVID-19 more effectively to prevent complications and encourage further research into therapies to prevent blood clots in these patients,” Dr. Wright said.

Dr. Wright’s associates in this study include: Thomas O. Vogler, PhD; Ernest E. Moore, MD, FACS; Hunter B. Moore, MD, PhD; Max V. Wohlauer, MD; Shane Urban, BSN, RN; Trevor L. Nydam, MD, FACS; Peter K. Moore, MD; and Robert C. McIntyre Jr., MD, FACS.

“FACS” designates that a surgeon is a Fellow of the American College of Surgeons.

Disclosures for this work: Drs. Ernest E. and Hunter B. Moore receive research support from Haemonetics and Instrumentation Laboratory .

Disclosures outside the scope of this work: Drs. Ernest E. and Hunter B. Moore hold stock options with Thrombo Therapeutics.

Support: REDCap is provided through the Colorado Clinical & Translational Sciences Institute (CCTSI) with the Development and Informatics Service Center (DISC) grant support (NIH/NCRR Colorado CSTI Gran Number UL1 RR025780).

Citation: Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. Journal of the American College of Surgeons. DOI: https://doi.org/10.1016/j.jamcollsurg.2020.05.007 

__
1
Giannis  D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127:104362; Johns Hopkins University. Johns Hopkins University Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/map.html (.) Accessed April 23, 2020; Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020; epub doi: 10.1111/jth.14850; Subramaniam S, Scharrer I. Procoagulant activity during viral infections. Front Biosci (Landmark Ed). 2018;23:1060-1081; ang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847;Wang ZF, Su F, Lin XJ, et al. Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1). Thromb Res. 2011;127(3):198-201; Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475-481; Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.

2 Activase. Drugs@FDA: FDA-Approved Drugs. Accessed May 16, 2020. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103172

*Drug definition revised in this copy: May 18, 2020

# # # 

About the American College of Surgeons
The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 82,000 members and is the largest organization of surgeons in the world. For more information, visit www.facs.org.

SEE ORIGINAL STUDY




Filters close

Showing results

1120 of 3395
Released: 24-Sep-2020 1:05 PM EDT
How do Americans view the virus? Anthropology professor examines attitudes, perceptions of COVID-19
Northern Arizona University

In her latest study, Northern Arizona University professor Lisa Hardy looks at how Americans’ attitudes and responses have changed during the time of the pandemic and how to many people, the virus is not a biological agent but instead a malicious actor.

Newswise: Center Awarded OSHA Susan Harwood Training Program Grant
Released: 24-Sep-2020 12:50 PM EDT
Center Awarded OSHA Susan Harwood Training Program Grant
Rutgers School of Public Health

The Rutgers School of Public Health’s Center for Public Health Workforce Development has received the U.S. Department of Labor Occupational Safety and Health Administration Susan Harwood Training Program Grant for the eleventh consecutive year.

Released: 24-Sep-2020 11:45 AM EDT
How the Loss of Black-Owned Doctors’ Offices May Worsen Health Disparities
Rutgers University-New Brunswick

Rutgers New Jersey Medical School experts discuss how the loss of Black-Owned doctors’ offices could affect primary care access in minority communities and what impact the COVID-19 pandemic is having in those communities.

Released: 24-Sep-2020 11:15 AM EDT
Preparing for asthma attacks during a pandemic
University of Texas Health Science Center at Houston

Cooler weather, pumpkins, and falling leaves – all things that kick off the most wonderful time of year, the holiday season. But for asthma sufferers, this could mean trouble because experts see an increase in asthma attacks toward the end of September.

Newswise: Double-lung transplant for COVID-19 patient performed by team of UTHealth physicians
Released: 24-Sep-2020 11:10 AM EDT
Double-lung transplant for COVID-19 patient performed by team of UTHealth physicians
University of Texas Health Science Center at Houston

Just 12 hours after undergoing a double-lung transplant, 70-year-old Francisco Medellin was sitting up in a chair pushing bike pedals – a seemingly simple act that was the culmination of hard work by a dedicated multidisciplinary team from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

Newswise: Antibodies protect against wide range of influenza B virus strains
22-Sep-2020 11:50 AM EDT
Antibodies protect against wide range of influenza B virus strains
Washington University in St. Louis

Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai. Together with an antibody that targets the other major kind of influenza viruses that infect people — influenza A — these antibodies potentially could form the basis of a broad-spectrum flu drug that could treat almost all flu cases.

Released: 24-Sep-2020 10:45 AM EDT
Uncovering a ‘suPAR’ culprit behind kidney injury in COVID-19
Michigan Medicine - University of Michigan

A new observational study finds patients in the hospital for COVID-19 have high levels of soluble urokinase receptor (suPAR), an immune-derived pathogenic protein that is strongly predictive of kidney injury.

Released: 24-Sep-2020 10:35 AM EDT
Climate pledges 'like tackling COVID-19 without social distancing'
University of Exeter

Current global pledges to tackle climate change are the equivalent of declaring a pandemic without a plan for social distancing, researchers say.

Released: 24-Sep-2020 10:10 AM EDT
Rebound or Permanent Slump? Possible Impacts of US COVID-19 Fiscal Policies
University of Virginia Darden School of Business

Fiscal policy is a powerful tool to combat economic downturns, but the results depend on decreasing inequality, an imperative to the efficacy of fiscal multipliers. As COVID-19 cases rise, new research offers insights into which fiscal policies may bolster the economy — and the other options, which may have long-term ramifications.

Released: 24-Sep-2020 5:05 AM EDT
Many Americans continue to maintain unhealthy lifestyle habits during COVID-19; overeating, alcohol drinking and marijuana use increase while exercise declines, reports USC Center for the Digital Future
USC Annenberg School for Communication and Journalism

After more than six months of living in a pandemic, large percentages of Americans continue to indulge in unhealthy lifestyle habits, including overeating and increased use of alcohol and marijuana — all while many are exercising less, according to a study of the cultural impact of COVID-19 conducted by the USC Center for the Digital Future (CDF).


Showing results

1120 of 3395

close
1.19959